Talphera, Inc. (FRA:R5XA)
Germany · Delayed Price · Currency is EUR | Market Cap | 54.71M +534.5% |
| Revenue (ttm) | 875.00 -96.3% |
| Net Income | -13.20M |
| EPS | -0.21 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.060 |
| Previous Close | 1.030 |
| Day's Range | 1.060 - 1.060 |
| 52-Week Range | 0.380 - 1.250 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Feds... [Read more]
News
Talphera Earnings Call Transcript: Q2 2026
NEPHRO-CRRT study enrollment is 75% complete, with top-line data and PMA submission targeted for the first half of 2027. Updated market research shows a 21% increase in projected CRRT procedures, and nafamostat's inclusion in KDIGO guidelines supports its commercial potential if approved.
Talphera Earnings release: Q2 2026
Talphera released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Talphera Quarterly report: Q2 2026
Talphera has published its Q2 2026 quarterly earnings report on August 12, 2026.
Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from pre...
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies...
Talphera Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and amendments to equity and stock purchase plans, with all proposals approved. No questions were raised by shareholders during the Q&A session.
Talphera assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of Talphera (TLPH) with a Buy rating and $3 price target The company is developing Niyad, a lyophilized formulation of nafamostat, as a regional anticoagulant for…
Talphera reports Q1 EPS (4c) vs. (10c) last year
Cash and investments balance was $21.1M as of March 31. “In early March, we announced the attainment of 50% enrollment in the NEPHRO CRRT study evaluating nafamostat. With continued steady…
Talphera Earnings Call Transcript: Q1 2026
Enrollment in the NEPHRO study surpassed 50%, with completion and top-line data expected in the second half of 2026. Cash balance was $21.1 million, with additional financing tranches available to support operations through potential Niyad approval.
Talphera Earnings release: Q1 2026
Talphera released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Talphera Quarterly report: Q1 2026
Talphera has published its Q1 2026 quarterly earnings report on May 13, 2026.
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
NEPHRO CRRT clinical study expected to be completed this year Cash and investments of $21.1 million at March 31, 2026 Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET SA...
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
Talphera initiated with a Buy at WestPark Capital
WestPark Capital analyst Ed Arce initiated coverage of Talphera (TLPH) with a Buy rating and $3 price target The firm says the company is brining the best continuous renal replacement…
Talphera Proxy statement: Proxy filing
Talphera filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Talphera Proxy statement: Proxy filing
Talphera filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Talphera Slides: Corporate presentation
Talphera has posted slides in relation to its latest quarterly earnings report, which was published on April 9, 2026.
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapi...
Talphera Registration statement: Registration filing
Talphera filed a registration statement on March 25, 2026, providing details about a securities offering with the SEC.
Talphera files to sell 639,931 shares of common stock for holders
06:03 EDT Talphera (TLPH) files to sell 639,931 shares of common stock for holders
Talphera Earnings Call Transcript: Q4 2025
The Nephro CRRT study reached 50% enrollment, unlocking $4.1M in financing and maintaining momentum toward a second-half 2026 PMA submission. Niyad is viewed as a highly promising, simpler alternative to current CRRT anticoagulants, with strong clinical enthusiasm for adoption if approved.
Talphera Annual report: Q4 2025
Talphera has published its Q4 2025 annual report on March 23, 2026.
Talphera Earnings release: Q4 2025
Talphera released its Q4 2025 earnings on March 23, 2026, summarizing the period's financial results.
Talphera reports Q4 EPS (6c) vs. (7c) last year
Reports cash and investments of $20.4M at December 31, 2025. “Earlier this month, we communicated reaching the 35-patient enrollment mark in the 70-patient nafamostat registrational study for CRRT. Si...
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 million All 12 clinical study sites now able to e...